Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM st

HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Th

Workday Named a Leader in Inaugural 2026 Gartner Magic Quadrant™ for Workforce Management Technol

HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms an

Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regu

HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-Ch

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology As

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake

Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City br

Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers an

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its s

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday

GSK subsidiary ​GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay ‌a unit of HUTCHMED (Chin

— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“

Workday Named a Leader in 2026 Gartner Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee E

AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhe

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive h

Findings build on the established success of the global SAFFRON and China SACHI trials, extending th

Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-a

Oracle Named a Leader in the 2026 Gartner Magic Quadrant™ for Supply Chain Management Suites PR N

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotaglifl

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlike

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biop

AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu wh

First global Phase III trial to show significant progression-free and overall survival benefits in t

— First global Phase III trial to show significant progression-free and overall survival benefits in

Oracle Adds New Fusion Agentic Applications and AI Agents to Help Organizations Improve Talent Manag

HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript

HUTCHMED NASDAQ: HCM reported first-half 2026 oncology revenue of $162 million, including $121 milli

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percen

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 202

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and l

HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The

Companies granted approval by the China National Medical Products Administration ("NMPA") fo

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and low

HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) tod

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

NDA supported by results from a Phase II registration trial in China —— Second most common form of l

— First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with syner

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent ta